Olivetolic Acid (Synonyms: Olivetolate, Olivetolcarboxylic Acid) |
Catalog No.GC41526
One-Click Copy Product Info
|
Olivetolic acid es un compuesto policético natural que sirve como precursor biosintético universal de todos los cannabinoides en Cannabis sativa
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 491-72-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Olivetolic acid es un compuesto policético natural que sirve como precursor biosintético universal de todos los cannabinoides en Cannabis sativa[1-2].
En un modelo de ratón del síndrome de Dravet Scn1a⁺/⁻, una sola inyección intraperitoneal de 10-100mg/kg de Olivetolic acid, Olivetolic acid (100mg/kg), aumentó significativamente en umbral de temperatura de las convulsiones tonic-clonic inducidas por el calor en aproximadamente 0.4°C, mostrando efectos anticonvulsivos[3].
References:
[1] Giangrossi M, Salamone S, Camola A, et al. Taglialatela-Scafati O, Chianese G, Gargiulo E, Nabissi M, Pollastro F. Biomimetic synthesis of rare cannabigerol-type cannabinoids and evaluation of their cytotoxic effect on human glioblastoma cell lines. Fitoterapia. 2025 Mar;181:106354.
[2] Ismed F, Farhan A, Bakhtiar A, et al. Crystal structure of olivetolic acid: a natural product from Cetrelia sanguinea (Schaer.). Acta Crystallogr E Crystallogr Commun. 2016 Oct 18;72(Pt 11):1587-1589.
[3] Anderson LL, Udoh M, Everett-Morgan D, et al. Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. J Cannabis Res. 2022 Jan 4;4(1):2.
| Experimentos con animales [1]: | |
Modelos animales | Scn1a+/- ratones |
Método de preparación | Los ratones se aclimataron a una sonda de temperatura rectal durante 5 minutos, luego recibieron una sola inyección intraperitoneal de vehículo o Olivetolic acid (10-100 mg/kg). Inmediatamente después, la temperatura corporal central se elevó 0,5 °C cada 2 minutos hasta la primera convulsión tónico-clónica generalizada (GTCS) con pérdida de postura o hasta que se alcanzó 42,5 °C. |
Forma de dosificación | 10-100 mg/kg; i.p. |
Áreas de aplicación | Olivetolic acid aumentó modestamente pero significativamente el umbral de convulsiones inducido por hipertermia en ratones Scn1a+/-, lo que indica una actividad anticonvulsiva comparable al cannabidiol en la misma dosis. |
References: | |
| Cas No. | 491-72-5 | SDF | |
| Sinónimos | Olivetolate, Olivetolcarboxylic Acid | ||
| Chemical Name | 2,4-dihydroxy-6-pentyl-benzoic acid | ||
| Canonical SMILES | OC1=CC(O)=C(C(O)=O)C(CCCCC)=C1 | ||
| Formula | C12H16O4 | M.Wt | 224.3 |
| Solubility | 50mg/mL in DMSO, 50mg/mL in DMF, 50mg/mL in Ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL |
| 5 mM | 891.7 μL | 4.4583 mL | 8.9166 mL |
| 10 mM | 445.8 μL | 2.2292 mL | 4.4583 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)